XML 74 R63.htm IDEA: XBRL DOCUMENT
v3.25.2

License and Collaboration Agreements - Additional Information (Details) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Mar. 01, 2024 | Feb. 07, 2024 | Jun. 30, 2025 | Oct. 31, 2024 | Sep. 30, 2019 | Jun. 30, 2025 | Jun. 30, 2024 | Mar. 31, 2024 | Jun. 30, 2025 | Jun. 30, 2024 | Dec. 31, 2024 | Jun. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Receivables from licensing and collaboration agreements |  |  | $ 76,868,000 |  |  | $ 76,868,000 |  |  | $ 76,868,000 |  | $ 4,722,000 |
Revenue |  |  |  |  |  | 110,565,000 | $ 2,168,000 |  | 227,198,000 | $ 213,288,000 |  |
Deferred revenue, current portion |  |  | 10,540,000 |  |  | 10,540,000 |  |  | 10,540,000 |  | 14,604,000 |
Deferred revenue, noncurrent |  |  | 14,667,000 |  |  | 14,667,000 |  |  | 14,667,000 |  | 17,095,000 |
Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  |  |  |  | 10,975,784 |  |  |  |
License and Collaboration Agreement | BMS |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment yet to be received |  |  |  |  |  |  |  |  |  |  |  | $ 90,000,000
License and Collaboration Agreement | Navire Pharma, Inc | BMS |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Initial transaction price for the license and collaboration agreement |  |  |  |  |  |  |  |  | 90,000,000 |  |  |
Allocation of transaction price for research and development |  |  |  |  |  |  |  |  | 19,800,000 |  |  |
Allocation of transaction price to licenses |  |  |  |  |  |  |  |  | 70,200,000 |  |  |
Revenue |  |  |  |  |  |  |  |  |  | 9,900,000 |  |
Deferred revenue |  |  | 0 |  |  | 0 |  |  | 0 |  | 0 |
Alexion License Agreements | Eidos |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |
Receivables from licensing and collaboration agreements |  |  | 1,000,000 |  |  | 1,000,000 |  |  | 1,000,000 |  | 600,000 |
Deferred revenue |  |  | 3,000,000 |  |  | 3,000,000 |  |  | 3,000,000 |  |  |
Deferred revenue, current portion |  |  | 1,000,000 |  |  | 1,000,000 |  |  | 1,000,000 |  | 3,000,000 |
Deferred revenue, noncurrent |  |  | 2,000,000 |  |  | 2,000,000 |  |  | 2,000,000 |  |  |
Upfront nonrefundable payment received |  |  |  |  | $ 25,000,000 |  |  |  |  |  |  |
Alexion License Agreements | License and Services Revenue |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Regulatory milestone payment receivable subject to achievement of regulator milestones |  |  | 30,000,000 |  |  | 30,000,000 |  |  | 30,000,000 |  |  |
Regulatory milestone payments received |  |  | 30,000,000 |  |  |  |  |  |  |  |  |
Alexion License Agreements | License and Services Revenue | Eidos |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 31,000,000 |  |  | 32,000,000 |  |  |
Alexion Agreements | Eidos |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  | 26,700,000 |  |  |  |  |  |  |
Upfront nonrefundable payment received |  |  |  |  | $ 25,000,000 |  |  |  |  |  |  |
Alexion Agreements | Eidos | Common Stock |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Shares issued |  |  |  |  | 556,173 |  |  |  |  |  |  |
Shares issued, price per share |  |  |  |  | $ 44.95 |  |  |  |  |  |  |
Aggregate purchase price |  |  |  |  | $ 25,000,000 |  |  |  |  |  |  |
Excess of purchase price over the value of common stock shares |  |  |  |  | $ 1,700,000 |  |  |  |  |  |  |
Bayer Exclusive License Agreement | Eidos |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Notice period for termination of agreement | 270 days |  |  |  |  |  |  |  |  |  |  |
Initial transaction price for the license and collaboration agreement | $ 135,000,000 |  |  |  |  |  |  |  |  |  |  |
Allocation of transaction price for research and development | 4,500,000 |  |  |  |  |  |  |  |  |  |  |
Allocation of transaction price to licenses | 130,500,000 |  |  |  |  |  |  |  |  |  |  |
Bayer Exclusive License Agreement | License and Services Revenue | Eidos |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 400,000 | 400,000 |  | 700,000 | 400,000 |  |
Bayer Exclusive License Agreement | License Revenue | Eidos |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  | 75,000,000 |  |  |
Bayer Exclusive License Agreement | Seller Parties | Eidos |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received | 135,000,000 |  |  |  |  |  |  |  |  |  |  |
Regulatory and sales milestone payments eligible to receive | 150,000,000 |  |  |  |  |  |  |  |  |  |  |
Sales milestones payments receivable upon the achievement | 450,000,000 |  |  |  |  |  |  |  |  |  |  |
Bayer Exclusive License Agreement | Seller Parties | EU Commission Regulatory | Eidos |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Regulatory and sales milestones | $ 75,000,000 |  |  |  |  |  |  |  |  |  |  |
Bayer License Agreements | Eidos |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Receivables from licensing and collaboration agreements |  |  | 3,900,000 |  |  | 3,900,000 |  |  | 3,900,000 |  | 0 |
Deferred revenue |  |  | 2,800,000 |  |  | 2,800,000 |  |  | 2,800,000 |  | 3,500,000 |
Deferred revenue, current portion |  |  | 1,000,000 |  |  | 1,000,000 |  |  | 1,000,000 |  | 1,300,000 |
Deferred revenue, noncurrent |  |  | 1,800,000 |  |  | 1,800,000 |  |  | 1,800,000 |  | 2,200,000 |
Bayer License Agreements | License and Services Revenue | Eidos |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 2,600,000 | 400,000 |  | 78,600,000 | 130,900,000 |  |
Bayer Commercial Supply Agreement and Bayer API Supply Agreement | License and Services Revenue | Eidos |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | 0 |  |  | 0 |  |
Kyowa Kirin Exclusive License | QED Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  | 100,000,000 |  |  | 100,000,000 |  |
Development and regulatory milestone payments yet to be received |  | $ 81,400,000 |  |  |  |  |  |  |  |  |  |
Notice period for termination of agreement |  | 180 days |  |  |  |  |  |  |  |  |  |
Initial transaction price for the license and collaboration agreement |  | $ 100,000,000 |  |  |  |  |  |  |  |  |  |
Allocation of transaction price for research and development |  | 30,900,000 |  |  |  |  |  |  |  |  |  |
Allocation of transaction price to licenses |  | $ 69,100,000 |  |  |  |  |  |  |  |  |  |
Kyowa Kirin Exclusive License | License and Services Revenue | QED Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 3,500,000 | 1,300,000 |  | 5,800,000 | 2,900,000 |  |
KKC License Agreements | QED Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Receivables from licensing and collaboration agreements |  |  | 100,000 |  |  | 100,000 |  |  | 100,000 |  | 0 |
Deferred revenue |  |  | 19,400,000 |  |  | 19,400,000 |  |  | 19,400,000 |  | 25,200,000 |
Deferred revenue, current portion |  |  | 8,500,000 |  |  | 8,500,000 |  |  | 8,500,000 |  | 10,300,000 |
Deferred revenue, noncurrent |  |  | $ 10,900,000 |  |  | 10,900,000 |  |  | 10,900,000 |  | $ 14,900,000 |
KKC License Agreements | License and Services Revenue | QED Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | $ 4,000,000 | $ 1,300,000 |  | $ 6,700,000 | $ 72,100,000 |  |

X
- Definition Allocation Of Transaction Price for Research and Development. + References No definition available. + Details
Name: | bbio_AllocationOfTransactionPriceForResearchAndDevelopment
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Allocation of transaction price to licenses. + References No definition available. + Details
Name: | bbio_AllocationOfTransactionPriceToLicenses
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Development and regulatory milestone payments yet to be received. + References No definition available. + Details
Name: | bbio_DevelopmentAndRegulatoryMilestonePaymentsYetToBeReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Excess of purchase price over the value of common stock shares. + References No definition available. + Details
Name: | bbio_ExcessOfPurchasePriceOverValueOfCommonStockShares
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Initial transaction price for license and collaboration agreement. + References No definition available. + Details
Name: | bbio_InitialTransactionPriceForLicenseAndCollaborationAgreement
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Notice period for termination of agreement. + References No definition available. + Details
Name: | bbio_NoticePeriodForTerminationOfAgreement
Namespace Prefix: | bbio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Regulatory and Sales Milestone Payments Eligible to Receive. + References No definition available. + Details
Name: | bbio_RegulatoryAndSalesMilestonePaymentsEligibleToReceive
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Regulatory and sales milestones. + References No definition available. + Details
Name: | bbio_RegulatoryAndSalesMilestones
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Regulatory milestone payment receivable subject to achievement of regulator milestones. + References No definition available. + Details
Name: | bbio_RegulatoryMilestonePaymentReceivableSubjectToAchievementOfRegulatorMilestones
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Regulatory milestone payments received. + References No definition available. + Details
Name: | bbio_RegulatoryMilestonePaymentsReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sales milestones payments receivable upon the achievement. + References No definition available. + Details
Name: | bbio_SalesMilestonesPaymentsReceivableUponTheAchievement
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Stock Issued With Premium + References No definition available. + Details
Name: | bbio_StockIssuedWithPremium
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront nonrefundable payment received. + References No definition available. + Details
Name: | bbio_UpfrontNonrefundablePaymentReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | bbio_UpfrontPaymentReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment yet to be received. + References No definition available. + Details
Name: | bbio_UpfrontPaymentYetToBeReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront payments received. + References No definition available. + Details
Name: | bbio_UpfrontPaymentsReceived
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=bbio_NavirePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_AlexionLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=bbio_EidosTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_AlexionAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_BayerExclusiveLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bbio_LicenseRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bbio_SellerPartiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bbio_EuropeanCommissionRegulatoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_BayerLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_BayerCommercialSupplyAgreementAndBayerAPISupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_KyowaKirinExclusiveLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=bbio_QEDTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_KKCLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |